Press Releases

UPDATE – DitchIt Detonates Iconic Twitter HQ Sign

Twitter Bird Iconic sign detonated SAN FRANCISCO, June 26, 2025 (GLOBE NEWSWIRE) — In a dramatic move that captured the spirit of Silicon Valley disruption, Ditchit — the emerging online marketplace and OfferUp competitor — made headlines by acquiring and detonating the original 560-pound Twitter bird sign once perched atop

DitchIt Detonates Iconic Twitter HQ Sign

Twitter Bird Iconic sign detonated SAN FRANCISCO, June 26, 2025 (GLOBE NEWSWIRE) — In a dramatic move that captured the spirit of Silicon Valley disruption, Ditchit — the emerging online marketplace and OfferUp competitor — made headlines by acquiring and detonating the original 560-pound Twitter bird sign once perched atop

Trident and Democratic Republic of Congo Sign Final Digital Identity Partnership and Launch Nationwide “DRCPass” Deployment

Final contract caps partnership, officially launches DRC’s national digital identification system; Web 3.0 digital identity in Africa; Trident appointed official e-KYC service provider. SINGAPORE and KINSHASA, June 25, 2025 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd. (“Trident” or the “Company,” NASDAQ: TDTH), a Singapore-based catalyst for digital transformation and

Synchronoss Achieves EU-U.S. Data Privacy Framework Certification

Reinforcing Global Leadership in Data Protection, Compliance, and Consumer Trust BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms for telecoms, today announced that it has achieved certification under the EU-U.S. Data Privacy Framework (DPF), administered by

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO